Eligible trials included those evaluating IL-17 or IL-23 inhibitors for PsO and documented PASI scores. Interleukin-17 (IL-17) inhibitors demonstrated faster psoriasis (PsO) clearance than Interleukin ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Although TNF inhibitors remain the first choice biologic ...
Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE registry ...
EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF’s have upheld their ...
-- ASC50 is an in-house discovered and developed oral small molecule interleukin-17 (IL-17) inhibitor for the treatment of multiple autoimmune and inflammatory diseases, including psoriasis. -- ...
This retrospective cohort study analysed the effectiveness and survival of patients with psoriasis undergoing therapeutic biologic dose spacing of secukinumab or brodalumab. The analysis included 80 ...
DUBLIN – Affibody AB is getting $10 million up front and up to $215.5 million in regulatory and sales milestones from a licensing deal with Inmagene Biopharmaceuticals Co. Ltd., in which the latter ...
Acelyrin, a biopharma firm, acquired licenses for izokibep, a potential treatment for inflammatory disorders, and completed a successful IPO, raising $621 million. Acelyrin's shares surged 35% after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback